COMMUNIQUÉS West-GlobeNewswire

Artelo Biosciences Announces Reverse Stock Split
06/03/2026
Shares Expected to Begin Trading on a Split-Adjusted Basis on March 10, 2026 SOLANA BEACH, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage [...]
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
06/03/2026
GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]
Tangram Therapeutics annonce l’administration de la première dose à un participant dans le cadre de l’essai RESTORE-MASH de phase I/II portant sur le TGM-312, un nouveau médicament expérimental à base d’ARNi
06/03/2026
L’essai RESTORE-MASH de phase I/II évaluera la sécurité, la pharmacocinétique et la pharmacodynamique du TGM-312 chez des volontaires en bonne santé et des patients atteints de MASH Les premières données sont attendues [...]
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
06/03/2026
ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in [...]
Verano to Report Fourth Quarter and 2025 Full Year Financial Results on March 12th, 2026
06/03/2026
CHICAGO, March 06, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial [...]
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
06/03/2026
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration On-track for VLS-01 [...]
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
06/03/2026
JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 JADE201 [...]
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
06/03/2026
- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On [...]
Prenetics Authorizes $40 Million Share Repurchase Program
06/03/2026
Management and Board Have Collectively Committed Up to $42.75 Million to Prenetics Stock Backed by $164 Million in Total Adjusted Liquidity, Zero Debt IM8 Targeting $180M to $200M in 2026 Full Year Revenue, and a Clear [...]
Anathapindika Shines Spotlight on World Sleep Day
06/03/2026
The Detox Supplement Manufacturer Connects Gut Health Resets and Brain Health to Better Sleep FORT LAUDERDALE, FL, March 06, 2026 (GLOBE NEWSWIRE) -- Sleep is a physiological requirement, and World Sleep Day emphasizes [...]
Anathapindika Spotlight Shines on Rare Disease Day (and How Detoxification Can Help)
06/03/2026
The National Observance Supports Those Managing Less-Than-Common Struggles. Anathapindika’s Supplements Can Help the Body Defend Itself. FORT LAUDERDALE, FL, March 06, 2026 (GLOBE NEWSWIRE) -- February 28th is Rare [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
06/03/2026
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of [...]
Claritas iPET™ Approved by Australia TGA to Supply the Medical Software Device for Image Processing Enabling Diagnostic Quality Images from Short Scan Time and/or Low Dose PET, PET-CT/MRI Scans
06/03/2026
LONDON and SYDNEY, March 06, 2026 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art image enhancement, noise reduction, segmentation and [...]
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
06/03/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Mok Shu Kam, Tony has [...]
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
06/03/2026
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who [...]
Fagron publishes its Annual Report 2025
06/03/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global player in pharmaceutical compounding, today publishes its [...]
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
06/03/2026
VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through [...]
Paingone Plus TENS Pen Featured in 2026 Consumer Report Examining FDA Clearance Status, TENS Pain Therapy Research, and Portable Pain Relief Device Verification
06/03/2026
A 2026 consumer research report examining Paingone Plus TENS pen searches, portable TENS pain relief device claims, FDA clearance status, published nerve stimulation therapy research, doctor endorsement context, and [...]

Pages